AIMS/HYPOTHESIS: The value of diagnostic categories of glucose intolerance for predicting type 2 diabetes is much debated. We therefore sought to estimate relative and population-attributable risk of different definitions based on fasting (impaired fasting glucose [IFG]) or 2 h plasma glucose concentrations (impaired glucose tolerance [IGT]) and to describe the associated clinical phenotypes. METHODS: We prospectively observed a population-based cohort of 1,963 non-diabetic participants (mean age 47 years), in whom an OGTT was performed at baseline and 7 years later. RESULTS: IGT was fivefold more prevalent (13.5%) than IFG. In both categories, participants were older, heavier, hyperinsulinaemic, hyperproinsulinaemic and dyslipidaemic compared with participants with normal glucose tolerance. Relative risk of incident diabetes was similar for IFG and IGT categories (3.73 [95% CI: 2.18-6.39] and 4.01 [95% CI: 3.12-5.14], respectively), but the population-attributable risk was fivefold higher for IGT (29% [95% CI: 26-32]) than for IFG (6% [95% CI: 5-7]). Isolated IFG carried no increase in risk. Lowering the threshold to 5.6 mmol/l raised the population-attributable risk of IFG to 23% (95% CI: 20-25); its contribution to diabetes progression, however, was largely due to co-existent IGT. In multivariate analysis adjusting for sex, age, familial diabetes and BMI, fasting and 2 h glucose were independent predictors. CONCLUSIONS/ INTERPRETATION: Fasting and 2 h glucose values are independent predictors of incident diabetes. Isolated IFG is not a high-risk condition; lowering the diagnostic threshold increases the population-attributable risk of IFG fourfold, but performing an OGTT captures additional diabetes progressors compared with the number identified by IFG.
AIMS/HYPOTHESIS: The value of diagnostic categories of glucose intolerance for predicting type 2 diabetes is much debated. We therefore sought to estimate relative and population-attributable risk of different definitions based on fasting (impaired fasting glucose [IFG]) or 2 h plasma glucose concentrations (impaired glucose tolerance [IGT]) and to describe the associated clinical phenotypes. METHODS: We prospectively observed a population-based cohort of 1,963 non-diabeticparticipants (mean age 47 years), in whom an OGTT was performed at baseline and 7 years later. RESULTS: IGT was fivefold more prevalent (13.5%) than IFG. In both categories, participants were older, heavier, hyperinsulinaemic, hyperproinsulinaemic and dyslipidaemic compared with participants with normal glucose tolerance. Relative risk of incident diabetes was similar for IFG and IGT categories (3.73 [95% CI: 2.18-6.39] and 4.01 [95% CI: 3.12-5.14], respectively), but the population-attributable risk was fivefold higher for IGT (29% [95% CI: 26-32]) than for IFG (6% [95% CI: 5-7]). Isolated IFG carried no increase in risk. Lowering the threshold to 5.6 mmol/l raised the population-attributable risk of IFG to 23% (95% CI: 20-25); its contribution to diabetes progression, however, was largely due to co-existent IGT. In multivariate analysis adjusting for sex, age, familial diabetes and BMI, fasting and 2 h glucose were independent predictors. CONCLUSIONS/ INTERPRETATION: Fasting and 2 h glucose values are independent predictors of incident diabetes. Isolated IFG is not a high-risk condition; lowering the diagnostic threshold increases the population-attributable risk of IFG fourfold, but performing an OGTT captures additional diabetes progressors compared with the number identified by IFG.
Authors: Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet Journal: Diabetes Care Date: 2003-11 Impact factor: 19.112
Authors: James S Pankow; David K Kwan; Bruce B Duncan; Maria I Schmidt; David J Couper; Sherita Golden; Christie M Ballantyne Journal: Diabetes Care Date: 2007-02 Impact factor: 19.112
Authors: F de Vegt; J M Dekker; A Jager; E Hienkens; P J Kostense; C D Stehouwer; G Nijpels; L M Bouter; R J Heine Journal: JAMA Date: 2001-04-25 Impact factor: 56.272
Authors: Monica Nannipieri; Clicerio Gonzales; Simona Baldi; Rosalinda Posadas; Ken Williams; Steven M Haffner; Michael P Stern; Ele Ferrannini Journal: Diabetes Care Date: 2005-07 Impact factor: 19.112
Authors: N G Forouhi; B Balkau; K Borch-Johnsen; J Dekker; C Glumer; Q Qiao; A Spijkerman; R Stolk; A Tabac; N J Wareham Journal: Diabetologia Date: 2006-03-09 Impact factor: 10.122
Authors: Jeff Cobb; Andrea Eckhart; Regis Perichon; Jacob Wulff; Matthew Mitchell; Klaus-Peter Adam; Robert Wolfert; Eric Button; Kay Lawton; Robert Elverson; Bernadette Carr; Margaret Sinnott; Ele Ferrannini Journal: J Diabetes Sci Technol Date: 2014-09-26
Authors: E Ferrannini; A Natali; E Muscelli; P M Nilsson; A Golay; M Laakso; H Beck-Nielsen; A Mari Journal: Diabetologia Date: 2011-03-22 Impact factor: 10.122
Authors: Xuemei Sui; Andrew S Jackson; Timothy S Church; Duck-Chul Lee; Daniel P O'Connor; Jihong Liu; Steven N Blair Journal: Ann Epidemiol Date: 2012-07-03 Impact factor: 3.797
Authors: Dianna J Magliano; Stefan Söderberg; Paul Z Zimmet; Bendix Cartensen; Beverly Balkau; Vassen Pauvaday; Sudhir Kowlessur; Jaakko Tuomilehto; K George M M Alberti; Jonathan E Shaw Journal: Diabetes Care Date: 2010-06-08 Impact factor: 19.112
Authors: M Larissa Avilés-Santa; Cynthia M Pérez; Neil Schneiderman; Peter J Savage; Robert C Kaplan; Yanping Teng; Erick L Suárez; Jianwen Cai; Aida L Giachello; Gregory A Talavera; Catherine C Cowie Journal: Prev Med Date: 2016-12-10 Impact factor: 4.018
Authors: Michael Bergman; Muhammad Abdul-Ghani; Ralph A DeFronzo; Melania Manco; Giorgio Sesti; Teresa Vanessa Fiorentino; Antonio Ceriello; Mary Rhee; Lawrence S Phillips; Stephanie Chung; Celeste Cravalho; Ram Jagannathan; Louis Monnier; Claude Colette; David Owens; Cristina Bianchi; Stefano Del Prato; Mariana P Monteiro; João Sérgio Neves; Jose Luiz Medina; Maria Paula Macedo; Rogério Tavares Ribeiro; João Filipe Raposo; Brenda Dorcely; Nouran Ibrahim; Martin Buysschaert Journal: Diabetes Res Clin Pract Date: 2020-06-01 Impact factor: 5.602